CTLA4 and cancer: To this end, we developed a novel chimeric receptor that can recognize CD80 and CD86 as tumor antigens on malignant B cells by combining the extracellular and transmembrane domains of CTLA4 with the intracellular signaling domains of CD28 and CD3z and explored its potential in cancer treatment.